Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
NCT05120570Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TAS-119 in graft-versus-host disease (GVHD), sponsored by Masonic Cancer Center. Primary endpoints: Optimal Dose of VIC-1911, Progression-free Survival at 1 year and 1 more. Started Mar 2022; status: completed.
02
Drugs
TAS-119
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05120570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05120570.